In the 1940s Klemperer grouped together as 'collagen diseases' a number of conditions such as systemic lupus erythematosus, scleroderma, and dermatomyositis. This idea was founded on the fact that a pathological lesion in these conditions was discernible in the connective tissues of the body. It is now clear, however, that there is no significant integral change in collagen in systemic lupus or in dermatomyositis although there is an apparent increase in the collagen content of some connective tissues in scleroderma. The designation 'collagen diseases' for this group of conditions is therefore inappropriate. If the term 'collagen disease', even in modified form, is to be retained it should more properly be applied to diseases in which measurable qualitative or quantitative abnormalities in collagen are a significant feature of the disorders in question.
Those diseases in which there is a qualitative change in the collagen molecule, as in some inherited disorders of collagen metabolism (see F. M. Pope and A. C. Nicholls (Pope and Nicholls, 1978) at page 95) could be conceived of as collagenopathies by analogy with the inherited disorders of haemoglobin metabolism, the haemoglobinopathies. Although those collagenopathies due to an enzyme deficiency are not strictly analogous to the qualitative haemoglobinopathies (where there is an amino-acid substitution in haemoglobin), the end result of the deficiencies is that the amino-acid sequence of collagen is altered. On the other hand, there are a number of diseases in which quantitative changes in the collagen content of tissue is of paramount importance in the destruction of organ architecture and functions. These diseases can collectively be termed collagen formative diseases. Some of the diseases which fit into this category are chronic valvular disease of the heart, atherosclerosis, dust diseases of the lungs, chronic nephritis, and cirrhosis.
Effects of collagen deposition
In all these diseases collagen is deposited in large quantities. The (Kefalides 1971) and that the hyalinised glomeruli of the end-stage kidney are conglomerates of types IV collagen and interstitial collagen (Nagle et al., 1960) .
Deposition of collagen in the liver in cirrhosis has two functional effects. Firstly, it completely disrupts the normal hepatic architecture so that the normal relationship between vascular inflow and outflow is destroyed. This leads to portal/hepatic venous and portal/hepatic arterial shunting of blood. Much of the vascular inflow therefore bypasses the nodular parenchyma (Hase, 1968) . Intrahepatic shunts also contribute to the development of portal hypertension. Secondly, the normal collagen content around hepatic sinusoids in regenerating nodules becomes modified. In the normal liver the sinusoids form an open system where plasma has free access to the sinusoidal villous border of the hepatocyte (Fig.  1) . In regenerating nodules, however, this open system becomes a closed one in which sinusoids are converted to capillaries with a subjacent basement membrane (Schaffner and Popper, 1963 Increased collagen production in liver disease could conceivably be due to increased collagen synthesis per 'fibroblast' or to an increase in the number of collagen-producing cells, all of which are functioning at a physiological rate. A priori, however, it seems more likely that a combination of both these mechanisms would operate in liver disease. Considering each mechanism separately, there are factors which may be responsible for the increase in the collagen productivity of individual cells. Chen et al. (1974) have claimed that when lymphocytes from patients with alcoholic hepatitis, hepatic schistosomiasis, and chronic active hepatitis are exposed to autologous liver in vitro they release macrophage inhibition factor and another 'Iymphokine' which stimulate collagen synthesis in fibroblasts up to twofold. The specificity of this 'Iymphokine' effect was not checked, however, since total protein synthesis in the fibroblast test system was not examined. (Fig. 4) . Similar fractions from normal liver homogenates produce virtually no stimulation (Fig. 4) . The factors have a specific effect on collagen synthesis itself; they have no effect on general protein synthesis in the same cultures when fractions from damaged and normal livers are compared (Fig. 5) . All the factors also stimulate prolyl hydroxylase activity four-to fivefold in the same cells . They are trypsin-sensitive (Table 5) and heat-stable (Fallon and McGee, 1978) , therefore they may be peptides. They not only increase the rate of collagen synthesis in cells but also produce a four-to sixfold increase in the amount of collagen secreted by the same cells (Table 6 ). Similar factors have now been found in human cirrhotic liver and in healing wounds (O'Hare and McGee, 1978) and in experimental pulmonary fibrosis (Thomson and Patrick, 1978) Fig. 5 Protein synthesis in L-929 fibroblasts after incubation with J-ml aliquots ofselectedfractions from a G25 Sephadex chromatogram of normal (---0) and CCI4-damaged mouse liver (0 0). This is the same chromatogram shown in Fig. 4 but after the culture was pulsed with 3, 4, 3H-proline as in Fig. 4 . Total protein synthesis was measured. (Data from Fallon and McGee, 1978 .)
The origin of collagen-stimulating factors is not known, but there are at least three obvious sources in liver disease. They may be derived from necrotic hepatocytes, from the degradation of some preformed inactive precursor in plasma (like the kinins), or they may be generated by macrophages which are active in all the diseases where these factors have been found. In relation to the macrophages, it is interesting to recall the work of Heppleston and Styles factor(s) is similar to collagen-stimulating factor isolated from liver and other tissues.
Collagen-producing cells
Collagen synthesis in liver disease might increase via an increase in the number ofcollagen-producing cells, all of which may function at a physiological rate. It is generally accepted that cells with the typical ultrastructure of fibroblasts are found in portal tracts in normal liver. Nevertheless, there was debate about the existence and type of cell within the liver lobule which is responsible for collagen production. There is now evidence which suggests that the perisinusoidal cell (Ito cell, fat storage cell) is the intralobular fibroblast. This evidence is based mainly on its ultrastructural features (McGee and Patrick, 1972 T'he cells also contain lipid droplets (Fig. 6) (McGee and Patrick, 1972) and chronic carbon tetrachloride injury (Kent et al., 1976) and that this increase is associated with fibrosis. As yet, nothing is known about the stimulus responsible for this proliferative response.
There are hints in other collagen formative disorders that macrophages release a factor(s) which may induce fibroblast proliferation (Leibovich and Ross, 1976) . It has been postulated also that platelets release a factor(s) which induces arterial smooth muscle cells to proliferate and grow into atherosclerotic plaques (Ross and Glomset, 1973 (Ohuchi and Tsurukuji, 1972) . However, mesenchymal cells isolated from liver, uncontaminated by hepatocytes, also contain this enzyme (Shaba et al., 1973) . More recently it has been shown that hepatocytes in vivo contain prolyl hydroxylase (Ooshima, 1977) . Tissue culture experiments also show that hepatocytes produce collagen in vitro (Sakakibara et al., 1976) . This last type of invitro study is difficult to interpret since it seems that virtually every cultured cell expresses a collagen gene (Langness and Udenfriend, 1974) . Perhaps both mesenchymal (for example, perisinusoidal) cells and hepatocytes make a contribution to the formation of the collagen matrix in liver.
Any hypotheses offered to explain the regulation of collagen production in liver disease must take account not only of the increased quantities of this protein formed but also of the qualitative change in the collagen type produced. In human cirrhosis there is a relative increase in the ratio of type I to type III collagen (Seyer et al., 1977) but there are no clues to how this switch occurs at a cellular or molecular level.
Conclusion
Many diseases in man (for example, hepatic cirrhosis) are characterised by aquantitativedisturbance in collagen formation. Such diseases may be grouped together as 'collagen-formative diseases'. In hepatic cirrhosis increased collagen accumulation is probably mainly due to increased collagen synthesis. This increase is partially mediated by the release of collagen-stimulating factors into the liver and by other undiscovered stimuli which cause collagenproducing cells to proliferate. The 'collagenformative disease' concept could be rejected on the grounds that collagen accumulation in cirrhosis is secondary to hepatocyte death, etc. However, there is no creditable evidence for this view. An advantage of the concept is that it may focus more attention on the destructive effects of collagen on organ function and may lead to the identification of therapeutic agents that will block collagen production in disease.
